Skip to main content
    P

    P3 Health Partners Inc (PIII)

    Official site

    HEALTHCARE • MEDICAL CARE FACILITIES • NASDAQ

    $2.41
    -0.29 (-10.74%)

    Last updated: Nov 16, 2026 at 4:00 PM ET

    P3 Health Partners Inc (PIII) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    P3 Health Partners (PIII) is expected to report earnings on Mar 24, 2027. In the quarter ended Sep 30, 2026, P3 Health Partners reported EPS of $0.07, above the -$7.40 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    48%(10/21)
    Avg Surprise
    -46.01%
    Streak
    3 Q

    Upcoming Estimates

    Reports Mar 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$5.73
    Range-$6.90 - -$4.41
    4 analysts
    Revenue Consensus
    $412.39M
    Range$388.67M - $432.60M
    4 analysts
    Reports May 12, 2027 (est.)Period ending Mar 31, 2027
    EPS ConsensusN/A
    RangeN/A
    Revenue Consensus
    N/A
    RangeN/A
    0 analysts

    Next Report

    PIII has an expected report date of Mar 24, 2027.

    PIII Earnings Call

    The latest PIII earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 21 quarters below that had an estimate, PIII beat 10, missed 9 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $396.34M, up 14.8% from $345.25M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.07-$7.40-$7.40 - -$7.40+100.95%BeatN/A10 up, 1 downNov 9, 2026$396.34M
    Jun 30, 2026-$0.63-$1.89-$2.10 - -$1.69+66.67%BeatN/A20 up, 0 downAug 10, 2026$386.38M
    Mar 31, 2026$0.32-$3.50-$3.73 - -$3.28+109.14%BeatN/A21 up, 0 downMay 14, 2026$386.39M
    Dec 31, 2025-$23.02-$9.47-$9.85 - -$9.08-143.21%MissN/A20 up, 2 downMar 26, 2026$384.81M
    Sep 30, 2025-$9.67-$6.04-$7.03 - -$4.31-60.10%MissN/A30 up, 2 downNov 14, 2025$345.25M
    Jun 30, 2025-$6.23-$4.30N/A-44.88%MissN/AN/A0 up, 0 downAug 14, 2025$355.79M
    Mar 31, 2025-$6.28$5.00N/A-225.60%MissN/AN/A0 up, 0 downMay 15, 2025$373.23M
    Dec 31, 2024-$0.36-$0.11N/A-227.27%MissN/AN/A0 up, 0 downMar 27, 2025$329.31M
    Sep 30, 2024-$14.50-$1.87-$3.00 - -$1.50-675.40%MissN/A40 up, 0 downNov 12, 2024$362.12M
    Jun 30, 2024-$4.50-$4.83-$5.50 - $4.50+6.83%BeatN/A41 up, 0 downAug 7, 2024$379.16M
    Mar 31, 2024-$8.00-$6.37-$7.50 - -$4.00-25.59%MissN/A30 up, 0 downMay 8, 2024$388.49M
    Dec 31, 2023-$0.22-$0.11-$0.19 - -$0.05-100.00%Miss-100.0%40 up, 0 downMar 28, 2024$346.86M
    Sep 30, 2023-$6.00-$11.00-$23.50 - -$3.00+45.45%BeatN/A40 up, 0 downNov 8, 2023$288.35M
    Jun 30, 2023-$4.50-$6.50-$12.00 - -$3.50+30.77%BeatN/A30 up, 0 downAug 7, 2023$329.09M
    Mar 31, 2023-$0.22-$0.67-$1.26 - -$0.22+67.16%BeatN/A20 up, 0 downMay 10, 2023$302.08M
    Dec 31, 2022$444.11-$45.50-$78.00 - -$13.00N/AN/AN/A20 up, 0 downMar 31, 2023$258.21M
    Sep 30, 2022-$13.50-$9.00N/A-50.00%MissN/AN/AN/ANov 14, 2022$248.26M
    Jun 30, 2022-$0.21-$0.23N/A+8.70%BeatN/AN/AN/AAug 31, 2022$269.45M
    Mar 31, 2022-$0.36-$0.36N/A0.00%In line-400.0%30 up, 0 downApr 25, 2022$273.54M
    Dec 31, 2021-$0.05-$0.24-$0.36 - -$0.12+79.17%BeatN/A30 up, 0 downJan 7, 2022N/A
    Sep 30, 2021-$0.13-$0.45N/A+71.11%BeatN/AN/AN/ADec 9, 2021$156.19M
    Jun 30, 2021-$0.33-$0.33N/A0.00%In lineN/AN/AN/AAug 19, 2021$144.59M
    Mar 31, 2021$0.12N/AN/AN/AN/AN/AN/AN/AApr 6, 2021$151.30M
    Last 23 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$45.20, after -$27.36 the year before. It was -$0.39 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$45.20N/A
    Dec 31, 2024-$27.36N/A
    Dec 31, 2023-$10.94-102.5%
    Dec 31, 2022$430.04N/A
    Dec 31, 2021-$0.39N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,300 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20264,2977
    2026Q2Jun 30, 20264,2327
    2026Q1Mar 31, 20263,6417
    2025Q3Sep 30, 20253,9268
    2025Q2Jun 30, 20255,9729
    2025Q1Mar 31, 20254,4788
    2024Q3Sep 30, 20245,2899
    2024Q2Jun 30, 20245,72111

    2026Q3 Earnings Call

    Opening remarks

    William Hoover Head of Investor Relations Thank you, operator, and thank you for joining us today. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under the U.S. Federal Securities Laws, including statements regarding our financial outlook and long-term target. These forward-looking statements are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise these forward-looking statements. We will refer to certain non-GAAP financial measures on this call, including adjusted operating expense, Adjusted EBITDA, Adjusted EBITDA per member per month, normalized Adjusted EBITDA, medical margin, medical margin per member per month, and cash flow. These non-GAAP financial measures are in addition to, and not a substitute for or superior to, the measures of financial performance prepared in accordance with GAAP. There are a number of limitations related to the use of these non-GAAP financial measures. For example, other companies may calculate similarly titled non-GAAP financial measures differently. Please refer to the appendix of our earnings release for a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures. Information presented on this call is contained in the press release that we issued today and in our SEC filings, which may be accessed from the Investor page of the P3 Health Partners website. I will now turn the call over to Aric Coffman, CEO of P3 Health Partners.

    Aric Coffman CEO Good afternoon, and thank you for joining us today to discuss our third-quarter results. It has been two and a half years since I began leading P3, and the changes we have made across the business continue to build on one another. Our third-quarter results reflect that work, with $21 million of Adjusted EBITDA, bringing our year-to-date Adjusted EBITDA to $101 million. As a result, we are raising the low end of our full-year Adjusted EBITDA guidance to $90 million, increasing the midpoint to $100 million. Our focus now is on building upon the durable foundation we have created. We have four areas of focus: medical cost management, quality and burden-of-illness documentation, disciplined growth, and refining our operations through people, process, and technology.

    Frequently Asked Questions About PIII

    When is P3 Health Partners's next earnings date?

    P3 Health Partners's next earnings report is expected for Mar 24, 2027.

    Did PIII beat earnings estimates last quarter?

    Yes. P3 Health Partners reported EPS of $0.07 for the quarter ended Sep 30, 2026, above the -$7.40 estimate, a 100.95% surprise.

    What EPS do analysts expect from PIII next quarter?

    The consensus EPS estimate for P3 Health Partners for the quarter ending Dec 31, 2026 is -$5.73 from 4 analysts, with estimates from -$6.90 to -$4.41.

    How often does PIII beat earnings estimates?

    P3 Health Partners beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -53.04%.